For the huge commercial success represented by GLP-1 agonists such as Mounjaro and Ozempic, particularly now in the context of treating obesity, they also present an operational nightmare for companies. That's as volumes of adverse events threaten to swamp existing safety workflows. Qinecsa’s Daniel O’Keeffe assesses the scale of the problem. The success of Glucagon-Like Peptide-1 (GLP-1) receptor agonists as modern weight-loss solutions has yet to peak. But it has already […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!